Table 4.
Market share (Before and after the inclusion of PER in the NRDL), %.
| Drugs | Before | After | |||||
|---|---|---|---|---|---|---|---|
| 2020 | 2021 | 2022 | 2023 | 2021 | 2022 | 2023 | |
| PER | 0.06 | 0.14 | 0.24 | 0.34 | 0.35 | 0.7 | 1.25 |
| LCM | 0.32 | 0.66 | 1.15 | 1.61 | 0.62 | 1.09 | 1.42 |
| ZNS | 0.48 | 0.41 | 0.34 | 0.29 | 0.39 | 0.31 | 0.24 |
| Total | 0.86 | 1.21 | 1.73 | 2.24 | 1.36 | 2.1 | 2.91 |
Market shares are derived using the overall market of oral anti-epileptic products as the prediction baseline and the data of PER in the baseline year (2020) as the data in Q1 of that year. The impact of ± 10% variation in the annual market share data of various drugs on the BI results after inclusion of PER in the NRDL is observed in DSA.
NRDL, National Reimburesement Drug List; PER, perampanel; LCM, lacosamide; ZNS, zonisamide.